Increasing prevalence of orthopedic illnesses and rising application of morphine for pain management are projected to boost market growth at a CAGR of 6.50%

Increasing Prevalence of Orthopedic Illnesses and Rising Application of Morphine for Pain Management are projected to boost market growth at a CAGR of 6.5%

Market Research Future (MRFR) has published a cooked research report on the “Global Morphine Market” that contains information from 2019 to 2035. The Morphine Market is estimated to register a CAGR of 6.5% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Morphine Market — Purdue Pharma (US), Mallinckrodt Pharmaceuticals (US), Teva Pharmaceutical Industries (IL), Mundipharma (GB), Hikma Pharmaceuticals (GB), Amgen (US), Sandoz (DE), and Boehringer Ingelheim (DE).

Market Highlights

The Global Morphine Market is accounted for to register a CAGR of 6.5% during the forecast period and is estimated to reach USD 34.53 Billion by 2035.

The market growth is primarily driven by the increasing prevalence of chronic pain, rising awareness of palliative care, and regulatory support for opioid use in medical treatments. Morphine continues to play a vital role in modern pain management protocols, with hospitals and clinics leading the usage segment.

Moreover, innovations in pharmaceutical formulations—including extended-release morphine and alternative delivery systems—are enhancing patient compliance and optimizing therapeutic outcomes. The integration of digital technologies and AI in drug management is also expected to elevate patient safety and efficacy tracking.

Companies such as Purdue Pharma, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries are strengthening their positions through strategic initiatives focused on digitalization, education, and manufacturing efficiency. For instance, Purdue Pharma partnered with a technology firm in 2025 to launch a digital adherence platform, while Mallinckrodt introduced an opioid safety education initiative for healthcare providers.

Additionally, emerging economies in the Asia-Pacific region are driving market expansion through healthcare infrastructure development and increasing demand for effective pain management therapies.

Segment Analysis

The Global Morphine Market has been segmented based on Dosage Form, Application, Distribution Channel, and End User.

• By Dosage Form: Injection (Largest) and Oral (Fastest-Growing)Injectable morphine dominates the market owing to its rapid onset of action and critical role in acute pain management. Meanwhile, oral morphine is gaining momentum for its convenience, affordability, and suitability in outpatient care, reflecting a shift toward patient-friendly pain management solutions.


• By Application: Pain Management (Largest) and Cold & Cough Suppressant (Fastest-Growing)The Pain Management segment holds the largest market share, driven by the rising incidence of chronic pain conditions. However, morphine’s use as a cold and cough suppressant is gaining attention in pharmaceutical innovations targeting respiratory care.


• By Distribution Channel: Hospital Pharmacies (Largest) and Online Pharmacies (Fastest-Growing)Hospital Pharmacies dominate due to controlled dispensing and direct patient care. Online Pharmacies, on the other hand, are growing rapidly with the expansion of telehealth services and consumer preference for convenient, home-based medication access.


• By End User: Hospitals & Clinics (Largest) and Ambulatory Surgical Centers (Fastest-Growing)Hospitals & Clinics lead due to structured care models and established pain management systems. Ambulatory Surgical Centers are emerging as key end users owing to the increasing number of outpatient surgeries and post-operative care needs.

Region Analysis

By Region, the Morphine Market is segmented into North America, Europe, Asia-Pacific, and Middle East & Africa.

• North America: Holds the largest market share (approx. 45%), driven by advanced healthcare infrastructure, high chronic pain prevalence, and favorable regulatory frameworks for opioid use. The U.S. remains the dominant market player with strong contributions from Purdue Pharma and Mallinckrodt Pharmaceuticals.


• Europe: Accounts for nearly 30% of the global market, with countries such as Germany and the UK leading growth. Regulatory agencies like the European Medicines Agency are facilitating structured opioid prescribing practices, balancing safety and access.


• Asia-Pacific: Represents the fastest-growing region, with about 20% of the global share. Rising healthcare accessibility, population growth, and government focus on palliative care are propelling the market in countries such as China and India.


• Middle East & Africa: Holds around 5% of the market and presents untapped opportunities driven by improving healthcare infrastructure and growing awareness of pain management. Countries like the UAE and South Africa are leading adoption efforts.

Key Findings of the Study

• The Global Morphine Market is expected to reach USD 34.53 Billion by 2035, at a CAGR of 6.5% during the forecast period.


• North America accounted for the largest market share in 2024.


• Based on Dosage Form, the Injection segment held the largest market share in 2024.


• Based on Application, the Pain Management segment dominated the market.


• Based on End User, Hospitals & Clinics led the market in 2024.


• Key market players include Purdue Pharma, Mallinckrodt Pharmaceuticals, Teva Pharmaceutical Industries, Mundipharma, Hikma Pharmaceuticals, Amgen, Sandoz, and Boehringer Ingelheim.

Related Reports

Morphine Market Size, Share, Industry Trends, Report 2035